An experimental cancer drug called CADD522 can potentially reverse post-menopausal bone loss and prevent midlife weight gain, according to a preclinical study published in the journal npj Drug Discovery. Researchers at the University of East Anglia found that the treatment strengthens skeletal microarchitecture and improves lipid metabolism in post-menopausal mice, offering a novel pathway to address concurrent metabolic and musculoskeletal challenges after menopause.
How CADD522 Targets the RUNX2 Protein
The experimental therapy was initially developed to block the RUNX2 protein, which drives the growth and spread of several cancers, including bone cancer. However, according to lead researcher Dr. Darrell Green from the University of East Anglia, scientists discovered an entirely unexpected benefit for post-menopausal health. During menopause, fluctuating hormones accelerate bone deterioration and trigger metabolic shifts. By blocking the RUNX2 protein, the drug stimulated new bone growth without interfering with the body’s normal bone-remodeling cycle, according to blood tests detailed in the study.
Existing osteoporosis medications predominantly work by suppressing bone loss, which can lead to complications during long-term use. In contrast, laboratory scans of post-menopausal mice treated with CADD522 for eight weeks revealed increased overall bone volume and better preservation of the delicate, honeycomb-like internal structures vital for skeletal strength. Preclinical testing also showed that the compound can be taken orally, is well tolerated across multiple animal species including rats and dogs, and metabolizes more slowly in human tissue than in rodents.
Addressing Midlife Weight Gain and Fat Accumulation
Beyond skeletal improvements, researchers observed significant metabolic changes in subjects receiving the treatment. According to the findings reported by The Daily Mail, treated mice weighed less than untreated controls despite consuming the exact same amount of food. They also accumulated less body fat and showed a reduction in fat deposits forming inside the bone marrow—a common post-menopausal process closely linked to declining bone health.
Brain tissue analysis further revealed that CADD522 reversed several menopause-related abnormalities in fatty acids. While levels of beneficial omega-3 fats such as DHA remained intact, other abnormal lipid patterns shifted back toward healthier profiles. While researchers did not directly test cognitive performance, the shifts in brain lipid chemistry suggest potential broader implications for managing menopause-associated health conditions.
Current Research Status and Future Human Trials
Osteoporosis currently affects approximately one in three women over the age of 50, frequently leaving patients vulnerable to painful, debilitating fractures. While numerous therapies exist, many patients struggle with compliance due to inconvenient dosing schedules or unpleasant side effects such as hot flashes, cramping, and strict posture requirements following administration.
Despite the promising preclinical results, experts emphasize that CADD522 remains in the early stages of development. The treatment has only been tested in animal models, and clinical trials in humans are required to confirm whether these bone-strengthening and metabolic benefits will successfully translate to people to lower fracture rates.
Worth a look